Protagenic Therapeutics Reports $1.4M Net Loss and Strategic Developments in 10-K Filing

Protagenic Therapeutics, Inc. reported significant financial developments in its recent 10-K filing for the fiscal year ending March 31, 2026. The company recorded a net loss of $1.4 million, a decrease from a loss of $3.6 million in the previous fiscal year, reflecting a 61% improvement. The total operating expenses increased to $4.5 million, up 74% from $2.6 million in the prior year, primarily due to heightened research and development activities associated with its lead product candidate, PT00114. The increase in expenses was also attributed to legal fees and stock compensation expenses, which were notably higher than in the previous year.

In terms of strategic developments, Protagenic underwent a reverse merger with Phytanix Bio, which was subsequently unwound in February 2026. This transaction temporarily expanded Protagenic's pipeline but was reversed due to ongoing litigation and strategic realignment. The company has since focused on advancing PT00114 through clinical trials, with plans to initiate a Phase IIa study in late 2026. The company also announced a restructuring plan aimed at transitioning to a virtual operating model, which is expected to reduce annual operating expenses by approximately $8 million.

Operationally, Protagenic has made strides in its clinical development, having commenced its first human trial for PT00114 in September 2023. The company anticipates completing the multiple-dose portion of its Phase I study by December 2025, with results expected to inform future studies. As of March 31, 2026, Protagenic had two full-time employees and engaged several consultants to support its operations. The company is also exploring strategic partnerships to enhance its market presence and expand its product pipeline.

Despite these advancements, Protagenic faces challenges, including a significant accumulated deficit of $4 million and the need for additional capital to fund ongoing operations. The company has indicated that its current cash resources are sufficient to support operations until the end of the third quarter of 2026, after which it will need to secure further financing. The filing also highlighted risks related to the company's common stock, which has been delisted from Nasdaq and is now traded on the over-the-counter market, potentially impacting liquidity and investor interest.

Looking ahead, Protagenic remains focused on advancing PT00114 through clinical trials and obtaining regulatory approvals. The company is optimistic about the potential of its lead candidate to address unmet needs in stress-related neuropsychiatric disorders, including treatment-resistant depression and anxiety. However, the path to commercialization remains uncertain, contingent on successful trial outcomes and the ability to secure necessary funding.